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The thyroid hormone receptor-coding locus, c-
erbAa, generates several mRNAs originating
from a single primary transcript that undergoes
alternative splicing. We have identified for the
first time two new transcripts, called TRDa1 and
TRDa2 [mRNA for isoform a1 and a2o ft h eT 3
receptor (TR), respectively], whose transcription
is initiated from an internal promoter located
within intron 7 of the c-erbAa gene. These two
new transcripts exhibit tissue-specific patterns
of expression in the mouse. These two patterns
are in sharp contrast with the expression pat-
terns of the full-length transcripts generated
from the c-erbAa locus. TRDa1 and TRDa2 mR-
NAs encode N-terminally truncated isoforms of
T3Ra1 and T3Ra2, respectively. The protein
product of TRDa1 antagonizes the transcrip-
tional activation elicited by T3 and retinoic acid.
This protein inhibits the ligand-induced activat-
ing functions of T3Ra1 and 9-cis-retinoic acid
receptor-a but does not affect the retinoic acid-
dependent activating function of retinoic acid
receptor-a. We predict that these truncated pro-
teins may work as down-regulators of transcrip-
tional activity of nuclear hormone receptors in
vivo. (Molecular Endocrinology 11: 1278–1290,
1997)
INTRODUCTION
Thyroid hormone T3 plays important roles during ver-
tebrate development, especially during amphibian
metamorphosis (1) and neurogenesis in mammals (2).
T3 is known to control the transcription of specific
genes through binding to nuclear receptors (T3Rs;
Ref. 3). Two loci encode the nuclear receptors of T3.
The c-erbAa locus encodes T3Ra1 whereas the c-
erbAb locus encodes T3Rb1 and T3Rb2 isoforms (4).
These receptors belong to a family of nuclear recep-
tors (5) including retinoic acid receptors (RAR), 9-cis-
retinoic acid receptors (RXR), vitamin D3 receptors
(VDR), peroxisome proliferator-activated receptors. All
these receptors contain a DNA-binding domain and a
ligand-binding domain and mediate ligand-dependent
transcriptional control of target genes. Activation or
repression of transcription requires binding of the re-
ceptors to specific recognition sequences in target
genes. Homodimerization and heterodimerization
among the various members of the nuclear receptor
family determine the target genes and repression/ac-
tivation activity. Heterodimerization allows cross-talk
between different signaling pathways (6). The pre-
ferred partners of T3Ra1 are the members of the RXR
family (3).
The mechanism of the transcriptional activity of
T3Ra1 seems to involve complex interactions with
many other nuclear proteins such as transcription fac-
tor IIB (TFIIB) (7), corepressors and coactivators (re-
viewed in Refs. 8 and 9), or cointegrators (10, 11). The
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ucts of the c-erbAa locus itself. TRa2 RNA results from
differential splicing of the TRa primary transcript (12).
The T3Ra2 protein lacks T3-binding and AF-2 domains
but retains a DNA-binding domain and can exert dom-
inant negative activity over T3Ra1 (13). The inhibition
mediated by T3Ra2 is at least partly due to competi-
tion for the DNA-binding sites and requires dephos-
phorylation of serine residues whithin the C-terminal
part of the protein (14). The physiological function of
T3Ra2 is still unknown, although its mRNA is ex-
pressed at higher levels than TRa1 in all tissues. N-
truncated T3Ra1 proteins have been detected in
chicken embryonic blood and are thought to result
from an initiation of translation at an internal site on the
TRa1 transcripts (15). These short proteins are in the
C-terminal part of T3Ra1, and some of them also lack
the DNA-binding domain. They have dominant nega-
tive activities that require the ninth heptad located in
the C-terminal part of T3Ra1. This ninth heptad is
known to be necessary for heterodimerization (16).
Such proteins have never been identified in mammals.
With the use of ES cells in which the c-erbAa gene had
been inactivated by homologous recombination, we
identified for the first time endogenous transcripts
generated from an internal promoter of the mouse
c-erbAa locus. These new transcripts were also de-
tected in wild type ES cells. They exhibit specific pat-
terns of expression in the mouse, and they direct the
synthesis of proteins that down-regulate transactiva-
tion elicited by T3Ra1 and RARa.
RESULTS
Identification of New Transcripts from the
c-erbAa Locus
ES cells containing an inactivated c-erbAa gene were
generated by homologous recombination. For this
purpose, exon 2 was disrupted after the second base
of the ATG initiation codon by inserting a plasmid
region containing the Lac Z gene, two transcription
stops, polyadenylation signals (Fig. 1A and Ref. 17),
and the neo
R gene driven by the b-actin promoter.
Heterozygous cell lines (c-erbAa
6) were grown at high
G418 concentration (18) to select for homozygous
clones in which both alleles of the c-erbAa gene were
disrupted (c-erbAa
2/2). Two independent c-erbAa
2/2
clones were isolated and used for subsequent analy-
sis. To check that both alleles of the gene were inac-
tivated, a RNAse protection experiment was per-
formed using 20 mg total RNA either from wild type or
from the two c-erbAa
2/2 ES cell lines. The I7E8 RNA
probe covering intron 7 and exon 8 was used (Fig. 2A).
After a 24-h exposure, only one protected fragment of
238 nucleotides, corresponding to TRa RNA, could be
detected in wild type cells under these conditions. This
fragment was not detected in the RNA of mutant
c-erbAa
2/2 ES cells (Fig. 2B, lane Cl10 and Cl20). The
absence of TRa transcripts was further confirmed by
RT-PCR using oligonucleotide 5S positioned in exon 5
and oligonucleotides 1A or 2A positioned in exons 9
(TRa1-specific) and exon 10 (TRa2-specific) as prim-
ers (see position in Fig. 1B). No amplification occurred
in c-erbAa
2/2 ES cells (Fig. 2D)
When RT-PCR was performed using oligonucleotide
8S (exon 8) as primer in 59-position (see position in Fig.
1B), amplification occurred in both c-erbAa
2/2 clones
Fig. 1. Modifications of the Structure of the Genomic Locus
of the c-erbAa Gene and Position of Oligonucleotides
The position of exons and introns is extrapolated from the
human c-erbAa gene structure (19). Exons are numbered 1 to
10. A, Modifications introduced in the c-erbAa locus by the
homologous recombination. Short horizontal arrows indicate
the position of each oligonucleotide. (a) Structure of the wild
type locus. Vertical arrows indicate transcription stops. b,
b-Actin promoter. TK, HSV thymidine kinase gene; ATG,
translation initiation codon of T3Ra1 and T3Ra2 proteins. (b)
Structure of the homologous recombination vector. (c) Struc-
ture of the modified locus. B, Structure of exons 5 to 10 of the
c-erbAa gene. P, PstI sites used in different cloning proce-
dures (see text). ac represents the part of exon 9 that is
common to TRa1 and TRa2 isoforms and a1( a 2) represents
the part of exon 9 (10) that is specific to a1( a 2) isoform.
Primer names are indicated under arrows. Sequences are
given in Materials and Methods.
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oligonucleotide as primer in the 39-position. These
observations led us to suggest that another RNA was
transcribed from an origin located upstream of exon 8
and was processed to generate both TRa1-like (called
TRDa1) and TRa2-like (called TRDa2) isoforms. To
identify the 59-end and origin of these transcripts, 59-
rapid amplification of cDNA ends (RACE) experiments
were performed using RNAs either from wild type or
from c-erbAa
2/2 ES cells.
A single DNA fragment was amplified from two inde-
pendent c-erbAa
2/2 ES cell clones and from the wild
type cells (data not shown). Sequence analysis of this
fragment revealed that the 39-end showed 100% identity
with the sequence of the mouse c-erbAa1 cDNA. The
alignment of the two sequences was interrupted at a
position corresponding to the junction between exons 7
and 8 (19). Further PCR cloning and sequencing of
mouse intron 7 showed that the first 33 nucleotides of
the amplified cDNA originated from the 39-end of intron
7. These results suggested that a transcript containing
sequences from intron 7 of the c-erbAa gene was pro-
duced in ES cells. To test whether this transcript was
initiated in intron 7, ribonuclease (RNAse) protection as-
says using the I7E8 probe were performed (Fig. 2A). With
10 mg of polyA
1 RNA as starting material, a triplet of new
protected fragments was detected, in addition to the
238-nucleotide fragment protected by the TRa RNA (Fig.
2C). The size of the protected RNA fragments ranged
between 292 and 310 nucleotides, corresponding to an
extension of 54 to 72 nucleotides at the 59-end com-
pared with the TRa-specific protected fragment. These
fragments were only detected in RNAs extracted from
ES cells and from lungs (data not shown), in agreement
with RT-PCR results showing that the highest levels of
TRDa1 and TRDa2 are detected in these tissues (see
below). These results show that a new mRNA is tran-
scribed from position 274/254 upstream from the intron
7/exon 8 boundary in the c-erbAa locus.
The presence of transcripts initiated within intron 7
was further assessed by RT-PCR amplification of RNA
from different species, using an oligonucleotide comple-
mentary to the 39-end of c-erbAa intron 7 from mouse,
human, or chicken. A cDNA was amplified from human
promonocytes U937, 7-day-old chicken embryos, and
mouse ES cells (Fig. 3A). These data suggest that tran-
scripts initiated in intron 7 may be present in all
vertebrates.
Identification of a Promoter within the c-erbAa
Locus
The putative promoter activity of intron 7 was then
investigated in a transient expression experiment. For
this purpose, a DNA fragment containing the last 276
nucleotides of mouse intron 7 and the first 236 nucle-
otides of exon 8 was inserted upstream from the chlor-
amphenicol acetyltransferase (CAT) coding sequence.
Its promoter activity was tested by transfection into
ES, HeLa, and COS7 cells, in comparison with a cy-
tomegalovirus (CMV) promoter. As shown in Fig. 3B,
the intron 7 in the sense orientation (S) efficiently pro-
moted the transcription of the CAT gene in the three
cell lines tested. In contrast, no significant expression
was found when intron 7 was inserted in the antisense
orientation. These data establish the existence of a
transcriptional promoter within intron 7 of the mouse
c-erbAa gene.
Sequence analysis of mouse intron 7 revealed
consensus binding sites for the transcription factors
AP-1, CAAT binding transcription factor (CTF), Sp1,
the glucocorticoid receptor, and the protooncogene
c-Ets (Fig. 3C). Comparison between human and
mouse sequences showed two conserved blocks
(Fig. 3C). Seventy three percent identity was found
between human and mouse in the last 62 bp of
intron 7, probably corresponding to conserved
splicing signals. Strikingly, a 42-nucleotide stretch
located at position 2130/289 (referring to the intron
7/exon 8 boundary) in the mouse sequence showed
75% identity with a human 2180/2138 fragment.
These homologies suggest that the promoter activ-
ity of intron 7 may be conserved in humans.
Molecular Cloning of TRa1 and TRa2 Short
Transcripts
Using 39-RACE methodology, we cloned the 39-end of
TRDa1 and TRDa2 RNAs using mutant c-erbAa
2/2 ES
cells RNA as starting material. A first round of PCR
Fig. 2. Identification of New Transcripts Generated from the
c-erbAa Gene in ES Cells
A, Structure of the I7E8 probe used for the RNase protec-
tion experiments. 238 is the size of the fragment protected by
the TRa mRNA. B, RNase protection with 20 mg total RNA
from wild type (CGR8) or c-erbAa
2/2 (Cl10, Cl20) ES cells. C,
RNase protection with 10 mg polyA
1 RNA from CGR8 cells.
D, RT-PCR with RNA from wild type (CGR8) and c-erbAa
2/2
(Cl10, Cl20) ES cells. Thirty five cycles (95 C, 15 sec; 56 C, 15
sec; 72 C, 30 sec) were carried out using oligonucleotides 5S
and 1A, 8S and 1A, 5S and 2A, and 8S and 2A.
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VIIS as the 59-primer (see position in Fig. 1B) to selec-
tively amplify cDNAs initiated in intron 7. A second
round was performed with either oligonucleotides 1S
or 2S to specifically amplify a1o ra 2 isoforms, respec-
tively. Products of amplification displayed 100% ho-
mology with TRa1o rT R a 2 in the coding regions.
39-Noncoding regions were homologous to those de-
scribed for rat or human TRa1 (gb M18028 and emb
X55005) and TRa2 RNAs (emb X07409 and emb
X55066). Antisense primers IXA and XA (Fig. 1B) were
designed from the 39-untranslated portions of TRDa1
and TRDa2 RNAs, respectively, and used together
with VIIS to amplify full-length TRDa1 and TRDa2
RNAs by RT-PCR. Each amplification generated one
single band, establishing the existence of TRDa1 and
TRDa2 RNAs in both c-erbAa
2/2 and wild type ES
cells (data not shown). Three clones obtained from
each amplification product had identical sequences to
the previously published mouse TRa1 and TRa2 RNA,
respectively (20) with the exception of the 59-short
intronic sequence. We can therefore conclude that the
Fig. 3. TRDa Transcripts Are Initiated in Intron 7
A, Amplification of a TRDa1 RNA in human (Hu), chicken (Ch), and mouse (Mo). The size of the PCR products is indicated in
base pairs on the left. Oligonucleotides used for RT-PCR with RNA from ES cells are VIIS and 1A. Cycle parameters are 95 C,
15 sec; 56 C, 15 sec; and 72 C, 15 sec. Thirty three cycles were performed. Oligonucleotides used for RT-PCR with U937 RNA
are hVIIS and 1A. Cycle parameters are 95 C, 15 sec; 56 C, 15 sec; and 72 C, 15 sec. Thirty three cycles were performed. Fifty
nanograms of reverse transcribed U937 RNA were used in both experiments. Oligonucleotides used for RT-PCR with 7-day-old
chicken embryo RNA are cVIIS and c9A. Cycle parameters are 95 C, 15 sec; 65 C, 15 sec; and 72 C, 15 sec. Thirty five cycles
were performed. Fifty nanograms of reverse transcribed polyA
1 RNA were used in the reaction. B, Intron 7 promoter activity: The
PstI-PstI c-erbAa genomic fragment was cloned upstream from a CAT expression vector in sense (S) or antisense (AS) orientation.
ES, HeLa, or COS7 cells were transfected with 5 mg of each plasmid. Cells were harvested 48 h later and analyzed by CAT-ELISA.
The results were normalized: 100% is the relative amount of CAT detected with 0.2 mg of CMV-CAT plasmid. C, Sequence of
intron 7: The last 26 nucleotides of exon 7 and the 60 first nucleotides of exon 8 are indicated in small capital characters. The
sequence of the intron 7 is written in capital letters. Consensus binding sites are boxed. The sequence of oligonucleotide VIIS is
underlined and arrowed. The PstI site within intron 7 is underlined. The segment carrying the transcription initiation sites is
overlined with a dashed line. Numbers 143 and 152 indicate the position of the putative ATG codons within exon 8. The human
sequence is indicated in lowercase letters, and homologies with the mouse sequence are indicated by stars.
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TRDa2, from an internal promoter located in intron 7.
The structure of these transcripts is depicted and
compared with the known structures of the TRa1 and
TRa2 transcripts in Fig. 4. Assuming that TRDa1 and
TRDa2 lack the first 1170 nucleotides of their full-
length counterparts, their length can be predicted to
be 4.5 kb and 1.5 kb, respectively (Fig. 4A). This pre-
diction was checked by Northern blot analysis of
polyA
1 RNA extracted from ES cells, using a mixture
of antisense oligonucleotides located within exons 8
and 9 as probes. Two transcripts of 4.5 (TRDa1) and
1.5 kb (TRDa2) were detected in addition to the 5.5-kb
(TRa1) and 2.5-kb (TRa2) transcripts (Fig. 4B, lane ES)
in ES cells. The ratio of the different isoforms was
TRDa1 5 0.5, TRa1 5 1, TRDa2 5 2, TRa2 5 10. The
shorter transcripts were not detected in liver (Fig. 4B,
lane L).
Expression of TRDa RNAs Is Regulated in Mouse
Tissues and During ES Cells’ Differentiation
The patterns of expression of TRDa1, TRa1, TRDa2,
and TRa2 mRNAs were analyzed in different mouse
tissues, using semiquantitative RT-PCR (Fig. 5A). As
expected, the TRa transcripts were detected in all
tissues. TRa1 displayed a predominant expression in
gut, heart, lung, muscle, and brain and a lower expres-
sion in spleen, liver, testis, thymus, and ES cells. TRa2
was found to be expressed predominantly in brain,
gut, heart, lung, kidney, and muscle. In contrast, TRDa
transcripts displayed a more restricted pattern of ex-
pression. The highest amount of TRDa1 was found in
lung. Lower amounts were detected in gut and in ES
cells, and no transcript was detected in muscle,
spleen, thymus, liver, and testis. The highest amount
of TRDa2 was found in ES cells and in lung. Lower
amounts were observed in gut and brain, and no tran-
script was detected in kidney, muscle, spleen, liver,
and testis. These data show that the TRa and TRDa
RNAs have distinct patterns of expression, suggesting
that their transcription may be differentially controlled.
Fig. 4. The TRa and TRDa Transcripts
A, Schematical representation of the transcripts generated
by the c-erbA a locus. Gray staining: region common to a1
and a2 isoforms. Light hatched blocks indicate region spe-
cific to a1-isoforms. Heavy hatched blocks show region spe-
cific to a2-isoforms. Black blocks indicate 59-end specific to
TRDa mRNAs. Upstream region from the c-erbAa gene and
the 59-end of the TRa mRNAs are not shown (horizontal
dashed blocks), and 39- untranslated regions of RNAs are
shown as lines. B, Identification of all TRa related transcripts
in ES cells (ES) and mouse liver (L) by Northern blot analy-
sis.The oligonucleotides used for hybridization were 9A, 15A,
and 3A (located in exons 9, 9, and 8, respectively). The
membrane was autoradiographed for 4 days with a XAR5 film
(Kodak, Rochester, NY).
Fig. 5. Pattern of Expression of TRDa Transcripts in the
Mouse
A, RT-PCR analysis of the expression pattern of long and
short transcripts in adult mouse tissues and in ES cells. Pairs
of oligonucleotides used to amplify TRa1, TRa2, TRDa1,
TRDa2, and HPRT cDNAs are 5S/1A, 5S/2A, VIIS/1A, VIIS/
2A, and HPRTs/HPRTa. Fifty nanograms of reverse-tran-
scribed RNA were used in each amplification reaction. Forty
cycles were performed to amplify TRDa2 cDNAs, 35 cycles to
amplify TRDa1 and TRa2 cDNAs, and 30 cycles to amplify
TRa1 cDNAs (95 C, 15 sec, 56 C, 15 sec, 72 C, 20 sec).
Twenty eight cycles (95 C, 15 sec; 52 C, 15 sec; 72 C, 15 sec)
were performed to amplify HPRT cDNA. B, Brain; G, gut; H,
heart; K, kidney; Li, liver; Lu, lung; M, muscle; S, spleen; Te,
testis; Th, thymus; ES, ES cells. B, RNase protection analysis
of RNA from undifferentiated or differentiated ES cells. Cells
were grown in the presence (1LIF) or absence (2LIF) for 4
days. Ten micrograms of polyA1 RNA obtained from each
culture were incubated with a I7E8 probe (cf. Fig. 2A) for
RNase protection analysis. The positions of specific bands
are indicated. The gel was exposed for4ht odetect the
c-erbAa transcripts and 30 h to detect the TRDa transcripts.
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the expression of TRa and TRDa transcripts during the
differentiation of ES cells. Using a RNAse protection
assay, we showed that 4 days after the induction of the
differentiation by removing leukemia inhibiting factor,
the transcripts initiated in intron 7 were no more de-
tectable, whereas the level of TRa RNAs increased
(Fig. 5B). These results were confirmed by RT-PCR
analysis (data not shown). They bring further evidence
for independent controls of the activities of both pro-
moters. Moreover, these data suggest that the prod-
ucts of the TRDa transcripts may be important in main-
taining the ES cells in an undifferentiated state.
Translation of TRDa1 and TRDa2 RNAs in HeLa
Cells
Both TRDa1 and TRDa2 cDNAs display open reading
frames starting from two potential translation initiation
codons located 43 and 52 nucleotides, respectively,
downstream from the first nucleotide of exon 8 (see
position in Fig. 3A). Interestingly, both codons are
highly conserved in fish, Xenopus, chicken, mouse,
rat, and human (22). The reading frames are identical
to those of TRa1 and TRa2. The predicted proteins
would be N-terminally truncated forms of T3Ra1o r
T3Ra2 proteins, with molecular weights of 16,000 and
26,000, respectively. They would lack the DNA-bind-
ing domain, the hinge region, the nuclear-addressing
signals, and the N-terminal part of the ligand- binding
domain of the full-length T3Ra proteins (Fig. 6 and
Refs. 23 and 24). Because none of these truncated
proteins would retain a complete ligand-binding do-
main, they would have lost the capacity to bind T3 (25).
All our attempts to detect the endogenous products
in ES cells have been unsuccessful. Like their full-
length counterparts T3Ra1 and T3Ra2, the endoge-
nous proteins translated from the TRDa1 and TRDa2
RNAs are probably expressed at low level in most
tissues. In addition, the available antibodies do not
have a sufficient affinity because endogenous T3Ra1
cannot be detected in ES cells either. To assess the
ability of the two TRDa transcripts to encode the pre-
dicted proteins, the TRDa1 and TRDa2 cDNAs were
cloned into pSG5 expression vector (pSGTRDa1 and
pSGTRDa2, respectively), which does not contain any
translation initiation signals, and transfected into HeLa
cells. Analysis of the cellular proteins by Western blot-
ting revealed that TRDa1 RNA encodes one single
polypeptide of approximately 16 kDa, called p16a1,
and TRDa2 RNA yields one single polypeptide of ap-
proximately 26 kDa, called p26a2 (Fig. 7A). The half-
life of these proteins in HeLa cells was estimated in
pulse-chase experiments to be 1 h for p16a1 and 2–3
h for p26a2 (Fig. 7B). The cellular localization of tran-
siently expressed p16a1 and p26a2 was investigated
by in situ immunofluorescence in HeLa cells. p16a1
exhibited both cytoplasmic and nuclear localization
(Fig. 7C, panel 1) whereas p26a2 was predominantly in
the cytoplasm (Fig. 7C, panel 2). These localizations
differ from that of nuclear receptors like T3Ra1, which
exhibit a strict nuclear localization (data not shown).
Functional Interference of p16a1 and p26a2 with
T3Rs and RARa in Vivo
Artificial constructs that express C-terminal portions of
the T3Ra1 receptor have been shown to behave as
repressors of the transactivation mediated either by
T3Ra1o rb yR A R a(26). Therefore, we investigated the
possibility that the p16a1 and p26a2 proteins might be
natural antagonists of nuclear receptors. We first ex-
amined the effect of these proteins on the T3-depen-
dent transcriptional activity of T3Ra1, as compared
with the well described inhibition exerted by T3Ra2.
One or 4 mg of pSGTRDa1, pSGTRDa2, or pSGTRa2
expression vectors were cotransfected with an ex-
pression vector for T3Ra1. Transcriptional activity was
revealed from a cotransfected reporter plasmid in
which the CAT gene is driven by a core globin pro-
moter downstream from a palindromic T3-responsive
element (inverted repeat; IR0). Data presented in Fig.
8A show that both p16a1 and p26a2 inhibited the
transcription mediated by T3Ra1 in a dose-dependent
manner. This repressing activity was comparable to
the one of TRa2. These inhibitory activities required
the translation of the cDNAs because another mutated
construct, pSGTRDT, which does not enable the pro-
duction of p16a1 but generates TRDa1 transcripts,
was unable to repress the transcriptional activation by
T3.
We checked whether this inhibition could be the
result of nonspecific effects on the transcriptional
machinery (Fig. 8B). Whereas p16a1 did not signif-
Fig. 6. Structure of the Proteins Produced by the c-erbAa
Locus
Numbers refer to amino acids of the T3Ra1 and T3Ra2
proteins. 256/259 indicates the putative positions of the NH2-
terminal methionine of p16a1 and p26a2. 369 and 319 are
the positions of the stop codons introduced to generate
N-terminally truncated mutants of p16a1. DBD, DNA-binding
domain; HR, hinge region; T3, ligand binding domain; t3/AF2,
t3 and AF2 domains. Gray staining indicates region common
to a1- and a2-isoforms. Light hatched blocks show region
specific to a1-isoforms. Heavy hatched blocks indicate re-
gion specific to a2-isoforms.
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b-actin promoters, p26a2 strongly repressed all
promoters. Therefore, p16a1 behaved as a specific
antagonist of the T3-dependent T3Ra1 activity, but
p26a2 had a more general inhibitory effect toward
transcription.
To map the inhibitory activity of p16a1, we gener-
ated truncated variants of this protein (see Fig. 6 for
the position of truncations) and investigated their abil-
ity to repress the transcriptional activity of T3Ra1. The
efficient production of all variant proteins in trans-
fected cells was checked by Western blot analysis
(data not shown). Figure 8C shows that a mutant pro-
tein that retained the N-terminal portion common to
p16a1 and p26a2 (amino acids 256 to 369) was still a
potent repressor. This protein does not contain the
ninth heptad repeat necessary for heterodimerization
of receptors with RXR (30). Moreover, a shorter trun-
cation mutant (256–319), which lacked most of the
heptad repeats involved in homodimerization of the
receptors, inhibited T3Ra1. This protein retained a
domain previously identified as t3 (31). In contrast, the
complementary C-terminal domain (320–410) dis-
played no inhibition.
We investigated the repressing activity of p16a1
toward different nuclear receptors associated with dif-
ferent hormone response elements, in the presence of
their ligand (Fig. 8D). A strong repression of T3Ra1
was observed in the context of the malic enzyme T3
response element (DR4-type). The activity of T3Rb1
was repressed both in the context of the IR0 and the
DR4 response element. The activity of endogenous
RARs on the RARb RA response element (DR5-type)
was only partially (60%) but reproducibly inhibited. In
contrast, the RA-dependent activation of the IR0 ob-
tained by the cotransfection of 0.2 mg of pSGRARa
was efficiently repressed.
Mechanism of Action of p16a1
We investigated the mechanism by which p16a1 could
repress the activities of the receptors. The transcrip-
tional activity of the receptors requires binding to DNA,
heterodimerization, and activation of transcription. We
tested in vivo the possible interference of p16a1 with
either of these three steps. To assay the effect of
p16a1 on DNA binding, we tested its activity on the
ligand-independent transcriptional repression of
RARa and T3Ra1. Figure 9A shows that the active
repression mediated by these unliganded receptors on
a IR0 response element was not affected by p16a1. In
agreement with these data, in vitro binding of T3Ra1t o
DR4 or palindromic response elements was unaf-
fected by p16a1, as assayed by gel shift experiments
(data not shown). These data rule out a squelching
activity of p16a1 toward the receptors, which would
either prevent binding of the receptors to DNA or their
nuclear transport.
We then tested the possibility that p16a1 could
interfere with the heterodimerization of the receptors
with RXR. Therefore, we used a double hybrid system
in which a Gal4 DNA-binding domain fused to either
RARa or T3Ra1 ligand-binding domain was coex-
pressed in HeLa cells together with a VP16-activating
domain fused to RXR ligand-binding domain. Their
transcriptional activity was revealed in the presence of
a reporter vector consisting of a CAT gene under the
control of four Gal4 binding sites upstream of a mini-
mal thymidine kinase (TK) promoter (UAS4CAT). Figure
9B shows that, whereas unliganded Gal4-RAR or
Fig. 7. Expression of TRDa cDNAs in HeLa Cells
A, Detection of the p16a1 and p26a2 proteins in whole cell lysates of HeLa cells transfected with 2 mg of pSGTRDa1o r
pSGTRDa2 expression vectors, respectively. The No. 21 antibody is used to detect the truncated proteins. B, Pulse chase
experiment measuring the half-life of the p16a1 and p26a2 proteins. C, Detection of p16a1 (1) and p26a2 (2) in HeLa cells
transfected with 1 mg of either pSGTRDa1 or pSGTRDa2 expressing vectors, using No. 21 antibody. Bar, 5 mm.
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tional activity, coexpression of either of them with
VP16-RXR produced a strong activation, which could
not be inhibited by p16a1. Therefore, p16a1 was un-
able to prevent the interaction between RARa and
RXRa or T3Ra1 and RXRa. This is consistent with data
from electromobility shift assays that showed that this
protein could not prevent or modify the binding of
T3Ra1-RXRa heterodimers to IR0 or DR4 response
elements (data not shown).
Finally, we tested the effect of p16a1 on the acti-
vating functions of T3Ra1, RARa, and RXRa. There-
fore, we used chimeric proteins consisting of the hinge
and ligand-binding regions of the T3Ra1, RARa, and
RXRa receptors fused to the DNA-binding domain
of Gal4 (27). These chimera were coexpressed with a
UAS4CAT vector. The activation of Gal4T3R or
Gal4RXR by their respective ligands was efficiently
inhibited by p16a1 (Fig. 9C). In contrast, the activation
of Gal4RAR by retinoic acid was unaffected. These
data suggest that p16a1 does not affect the activating
function of RARa but interferes with the transcriptional
activation domains, or activating functions, of T3Ra1
and RXRa.
The absence of inhibition of the activating function
of RARa is in apparent contradiction with data pre-
sented in Fig. 8D showing that the activity of the full-
length receptor on different response elements could
be at least partially inhibited by p16a1. We repeated
the experiment described in Fig. 8D, using 1 mg pS-
GRARa (Fig. 9D). We assumed that, in these new
conditions, RARa homodimers were the predominant
active complex. Given this assumption, we expected
that raising the amount of RXRa would result in the
preferential formation of heterodimers, leading to an
enhanced activation of the IR0 (27). Indeed, cotrans-
fection of 1 mg pSGRARa and 0.3 mg pSGRXRa pro-
duced a 2.2-fold enhanced RA-mediated activation of
IR0, as compared with the activation observed with
RARa alone. Interestingly, p16a1 was unable to inhibit
the activity of homodimers but reduced the activity of
the heterodimers by about 60%, as was observed
using the DR5 response element. We conclude that
p16a1 can antagonize the ligand-dependent activa-
tion of RARa, but only when it acts as RAR-RXR
heterodimer.
RARa was measured by transfecting HeLa cells with 0.2 mg
pSGRARa (provided by Professor P. Chambon, Strasbourg,
France) and 0.8 mg IR0 globinCAT, or 0.4 mg RAREb TKCAT
(DR5, provided by Professor P. Chambon). In every assay, 4
mg of either pSGTRDT (0) or pSGTRDa1 (4) were cotrans-
fected. The transfected cells were incubated in the presence
or absence of 10
27 M T3 or 10
26 M all-trans-RA for 24 h. In the
absence of hormone, the relative amount of CAT detected
was very low (,1% of the relative amount in presence of
hormone). The results of the experiment presented in this
figure have been reproducible in at least four independent
experiments.
Fig. 8. Effect of p16a1 and p26a2 on the Transcriptional
Activity of Different Promoters and Nuclear Receptors on
Their Responsive Elements in HeLa Cells
All results are expressed as the percentage of CAT
amount. A, Effect of p16a1 and p26a2 on the transcriptional
activity of liganded T3Ra. The transcriptional activity of
T3Ra1 was measured by transfecting HeLa cells with 0.8 mg
of IR0 globinCAT (IR0; Ref. 41) together with 1 mgo fp S -
GTRa1 (provided by Dr B. Vennstro ¨m, Sweden). One or 4 mg
of translationally silent vector (DT) or of vector encoding
T3Ra2, p16a1 (p16), or p26a2 (p26) was cotransfected. Each
transfection mixture was completed with pSG5 plasmid up to
4 mg of SV40-containing plasmid. Activities were measured
after addition of 10
27 M T3 for 24 h in 1% serum. B, Specificity
of the activities of p16a1 and p26a2: 0.1 mg of CMV-CAT, 2
mgo fb -actin CAT, or 2 mg of SV40-CAT were used in the
transfections; 4 mg of pSG5 (solid bars), pSGTRDa1( open
bars), or pSGTRDa2( dotted bars) was cotransfected. C,
Mapping of the inhibitory activity within p16a1. The experi-
mental conditions are as in panel A. Four micrograms of
pSG5 vector carrying either mutant TRDT( 2 ), mutant 256–
369, mutant 256–319, or mutant 320–408 were cotrans-
fected. D, Effect of p16a1 toward T3Ra1, T3Rb1, and RARa.
The transcriptional activity of T3Ra1 on the DR4 response
element was measured by cotransfecting 1 mg pSGTRa1 and
0.4 mg malic enzyme TRE TK CAT (DR4; Ref. 41). The activity
of T3Rb1 was measured by transfecting 1 mg pSGTRb1
together with either 0.8 mg IR0 globin CAT or 0.4 mg malic
enzyme TRE TK CAT plasmids. The transcriptional activity of
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All the cDNAs reported to date for the c-erbAa locus
correspond to mRNAs initiated by the c-erbAa pro-
moter (5): TRa1, coding for a T3 receptor, and TRa2,
coding for a protein that does not bind T3. We have
cloned and characterized two new transcripts of the
c-erbAa locus: TRDa1 and TRDa2, which begin in
intron 7 and are otherwise identical to the 39-part of
TRa1 and TRa2, respectively. These transcripts were
first identified in c-erbAa
2/2 ES cells, but they were
subsequently cloned from wild type ES cells. They
were also found in several wild type mouse tissues.
They were detected in chicken and in human, suggest-
ing that they are probably present in all vertebrates.
These data show unambiguously that these isoforms
are natural products of this locus and that they are not
the result of c-erbAa gene inactivation in c-erbAa
2/2
ES cells.
The promoter responsible for the transcription of
these isoforms is located in intron 7, and we confirmed
its activity in several cell types. The existence of a
specific transcriptional control of the expression of the
TRDa RNAs through this promoter is further sug-
gested by the differences observed in the patterns of
expression of the TRDa and TRa transcripts. The op-
posite variation of their amount during the differentia-
tion of ES cells suggests that the regulation of the
c-erbAa promoter is different from that of intron 7
promoter. The mRNAs generated by the intron 7 pro-
moter are spliced to generate the a1o ra 2 isoforms,
suggesting that the mechanisms that control the splic-
ing do not require the presence of sequences up-
stream of exon 8.
N-terminally truncated T3Ra proteins of 27 to 46
kDa had previously been described in chicken (15).
These proteins can exert a dominant negative activity
toward T3Ra1 and RARa transcriptional activation
(26). We have shown that the product of the TRDa1
mRNA that we have identified, p16a1, also has a dom-
inant negative activity toward T3Ra1, T3Rb1, and
RARa. This protein does not affect receptor-indepen-
dent transcription. In contrast, analyzing the function
of p26a2 is hindered by the fact that it can repress the
activity of all promoters tested to date, suggesting a
broad range of action. This might involve a nonspecific
inhibition of general transcription factors as was pre-
viously hypothesized for T3Ra2 (29). However, we
cannot exclude the possibility that p26a2 may also
have a specific inhibitory action toward nuclear recep-
tors, as was shown for T3Ra2 (14). The exact mech-
anism responsible for the inhibitory activity of p16a1i s
still unclear. Our data rule out the possibility that
p16a1 may prevent the receptors from forming het-
erodimers with RXRs or from binding to DNA. They
rather suggest that it exerts its action by preventing
the activity of a coactivator normally recruited by T3R
or RXR. The fact that the activating function of RARa
is not affected by p16a1 is consistent with the ab-
Fig. 9. Effect of p16a1 on Ligand-Independent Repression,
Heterodimerization, and Transcriptional Activation
A, Effect of p16a1 on the repression activity of unligan-
ded receptor. Transfection experiments are as in Fig. 8, A
or C, except that no ligand was added. Zero or 4 mgo f
p16a1 expressing vector pSGTRDa1 was cotransfected.
Four micrograms of pSGTRDT were used as control. The
results are expressed as the percentage of the amount of
CAT enzyme produced under the control of the IR0 globin
promoter. B, Effect of p16a1 on the heterodimerization
between RARa or T3Ra1 and RXRa: 0.4 mgo f
(UAS)4TKCAT reporter plasmid was cotransfected with
0.25 mg of pCMXGal4-RARa (GalRAR) or pSVGal4-TRa1
(GalT3R) in the presence or absence of 0.5 mgo fp C -
MXVP16-RXRa (VPRXR). C, Effect of p16a1 on the acti-
vating functions of T3Ra1, RARa, and RXRa: 0.4 mgo f
(UAS)4TKCAT reporter plasmid was cotransfected with
0.25 mg of either pCMXGal4-RARa (GalRAR), pCMXGal4-
RXRa (GalRXR), or pSVGal4-T3Ra (GalT3R). Two micro-
grams of pSGTRDa1 and 2 mg of pSGTRDT (2), or 4 mgo f
pSGTRDa1 (4), were cotransfected. Four micrograms of
pSGTRDT (0) were co-transfected in the control experi-
ments. The cells were treated by 10
28 M of all-trans-reti-
noic acid (RA) or of 9-cis-RA. D, Effect of p16a1o nR A R a /
RARa homodimers and RARa/RXRa heterodimers. The
activity of RARa/RARa homodimers was measured using 1
mg pSGRARa and 0.8 mg IR0 Globin CAT; the activity of
RARa/RXRa heterodimers was measured by cotransfec-
tion of 1 mg pSGRARa, 0.3 mg pSG RXRa, and 0.8 mg IR0
Globin CAT. Four micrograms of either pSGTRDT (0) or
pSGTRDa1 (4) were cotransfected. The cells were treated
by 10
26 M all-trans- retinoic acid (RA). The results of the
experiment presented in this figure have been reproducible
in at least four independent experiments.
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erodimerization of RARa with RXRa generates a com-
plex in which both partners undergo interdependent
conformational changes in response to different li-
gands. The transcriptional activities of this complex
can be at least partially antagonized by p16a1. Since
the proper activating function of RARa is not inhibited,
this suggests that, in heterodimers, the activating
function of RXRa is the main target of p16a1. To date,
no cofactor of nuclear receptors that interacts with
T3Rs and RXRs, but does not bind to RARs, has been
identified. Using C-terminally truncated mutants, we
have shown that the region of p16a1 that contains
amino acids 256 to 319 is sufficient to perform inhibi-
tion. This region contains four heptad repeats and the
t3 domain that provides transcriptional activity when
fused to the Gal4 DNA-binding domain (31). However,
no protein is known to interact with this region. A
possibility would be that the t3-domain, which is hid-
den within the T3Ra1 protein (32), is able to bind and
sequester a coactivator when exposed at the N-ter-
minus of p16a1. If this coactivator is one of the factors
normally recruited by AF-2 in the presence of ligand,
then it will not be available in the presence of p16a1.
Alternatively, the t3-domain within the receptor may
be exposed in some circumstances during the pro-
cessing of the protein and recruit a factor essential for
its activity. The interaction between p16a1 and the
target factor may take place either in the nucleus or in
the cytoplasm because p16a1 can be found within
both compartments. This interaction might result, for
example, in sequestering of the coactivator in the cy-
toplasm. Identification of this target factor will be nec-
essary to further understand the mechanisms of inhi-
bition by p16a1.
The biological functions of the proteins p16a1 and
p26a2 are unknown. Our data suggest that p16a1 may
block some of the functions of the nuclear receptors,
such as transcriptional activation of target genes,
without affecting other functions such as the activities
of aporeceptors. In contrast, p26a2 may have a
broader spectrum of repressive activities. We propose
that these truncated proteins could work as negative
regulators of nuclear receptors activity in vivo. ES cells
harboring a homozygous deletion of the c-erbAa locus
that includes exon 8 have been generated, thus pre-
venting the synthesis of both TRa and TRDa tran-
scripts (32a). Interestingly the authors have reported
that these cells are more responsive to RA treatment
than wild type ES cells, whereas our c-erbAa
2/2 cells,
producing TRDa but no TRa mRNAs, behave as wild
type ES cells (our unpublished data). Therefore this
enhanced response to RA could be explained by the
disappearance of an inhibitor of the transcriptional
activation pathway of the RARs that is still present in
our c-erbAa
2/2 cells. We propose that p16a1 and
p26a2 could be such inhibitors. It could be argued that
the ratio between the pSGTRDa and pSGTRa1 vec-
tors that must be reached to obtain inhibition in tran-
sient expression experiments in HeLa cells is very high
as compared with the respective levels of endogenous
transcripts in ES cells. According to the coactivator
hypothesis, the amount of p16a1 necessary to achieve
inhibition within a given cell must be proportional to
the amount of target coactivator present in this cell.
This amount is probably different according to the cell
type considered. Therefore, a smaller amount of
p16a1 may be required to obtain full inhibition in ES
cells than in HeLa cells, if we assume that the amount
of coactivator is lower in ES cells than in HeLa cells.
We propose that the function of p16a1 and p26a2i n
ES cells could be to prevent the activation of T3 or RA
receptors by low levels of exogenous ligands. They
could therefore participate in the maintenance of ES
cells in the undifferentiated state. This hypothesis is
supported by the observation that TRDa transcripts
are expressed in undifferentiated ES cells but disap-
pear upon differentiation as the level of long tran-
scripts increases.
The activity of truncated proteins as potent inhibi-
tors of their full-length counterpart is now well estab-
lished. For example, the same locus generates a tran-
scriptional activator LAP (liver-enriched transcriptional
activator protein) but also a truncated isoform LIP
(liver-enriched transcriptional inhibitory protein) which
behaves as an inhibitor of LAP (33). In the CREM
(cAMP response element modulator) locus an inhibi-
tory truncated isoform is produced from an internal
promoter (34). In the nuclear hormone receptor family
several recently cloned truncated products exhibit in-
hibitory properties. VDR0 (vitamin D receptor) (35) and
RARg (36) are inhibited by the truncated isoforms
VDR1 and RARbm382, respectively. In both cases,
activators and repressors are produced by the same
locus. Inhibition of T3R and RAR activities by the trun-
cated protein p16a1 is a novel example of this mech-
anism of regulation.
MATERIALS AND METHODS
Cells, Vectors, Transfections, and Reagents
CGR8 (ES) cells were cultured as previously described (37).
HeLa cells were transfected using a calcium phosphate pro-
cedure, as previously described (38). Quantitative determina-
tion of CAT enzyme was carried out using the CAT-ELISA kit
(Boehringer Mannheim, Meylan, France) and a kinetic micro-
plate reader (Molecular Devices, Menlo Park, CA). Gal4DBD-
hRARaLBD, Gal4DBD-hRXRaLBD, and VP16-RARa expres-
sion vectors are gifts from Dr R. Evans (27). pCAT4, in which
four copies of the Gal4-binding sites are cloned upstream of
a thymidine kinase minimal promoter, is a gift from Dr. Bus-
slinger. RAR-specific ligand Ro 40–6055 and RXR-specific
ligand Ro25–7386 are gifts from Dr. Michael Klaus from Hoff-
man LaRoche (Nutley, NJ).
Homologous Recombination and Production of
Homozygous ES Cells
The replacement vector, aHRVTK, was constructed by se-
quential insertion of genomic fragments of the mouse c-
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plasmid was first generated by replacing the Rous sarcoma
virus long terminal repeat driving the neo
R gene by a rat
b-actin promoter (kindly provided by R. Beddington, Mill Hill,
England). The genomic fragments were cloned from a 129/SV
mouse genomic library (gift from Dr J. P. Magaud, Lyon,
France) using an exon 1-specific probe. The 59-fragment was
synthesized by PCR amplification using oligonucleotides RS
and RA as primers (Fig. 1A), then cloned into pGNAb to
generate pGNAb59. The 39-fragment was first selected as a
subgenomic fragment hybridizing to an exon 2-specific oli-
gonucleotide and treated with Bal31 nuclease to remove
remaining exon 2 sequences. Digestion products were in-
serted into pGNAb59 to generate aHRV. A XhoI-SalI HSV-TK
fragment isolated from MC1TK (gift of Dr Capecchi) vector
was cloned into SalIi na HRV to generate the targeting vector
aHRVTK (Fig. 1A).
ES cells were electroporated with 40 mg aHRVTK vector
linearized by SalI digestion (250 V and 500 mFarads). Cells
were selected in 250 mg/ml G418. Neo-resistant clones were
picked up, amplified, and screened by PCR and Southern
blot. Two independent heterozygous clones were cultured in
2 mg/ml G418 to generate homozygous cells (18). G418-
resistant clones were screened for the disruption of both
alleles of the c-erbAa gene by Southern blotting.
RT-PCR Analysis
RNAs were extracted by a guanidinium thiocyanate/acidic
phenol method. Oligonucleotides were from Genset (Paris,
France). Their positions are displayed in Fig. 1, and their
sequences are given below. Reverse transcription was per-
formed as follows, unless specified: 1 mg total RNAs and 0.5
mg random primers (Promega, Madison, WI) were mixed in 10
ml, heated to 68 C for 5 min, and cooled to 37 C. Ten
microliters of polymerization mix (100 mM Tris-Cl, pH 8.3, 150
mM KCl, 20 mM dithiothreitol, 6 mM MgCl2, 0.5 mM each
deoxynucleoside triphosphate) were added, and the mixture
was incubated at 37 C for 1 h. The reaction was stopped by
heating at 68 C for 5 min. PCR was performed using Goldstar
thermostable polymerase (Eurogentech, Seraing, Belgium)
on a Perkin Elmer (Norwalk, CT) 9600 thermocycler. The
reaction was performed in Goldstar reaction buffer containing
2m MMgCl2 and using 100 ng of each oligonucleotide and 0.3
U of enzyme in a final volume of 50 ml. The thermocycler was
preheated to 95 C before the introduction of the reaction mix.
The cycle parameters are indicated in the figure legends.
Molecular Cloning of TRDa1 and TRDa2 cDNAs, Intron
7, and Subclonings
59-Ends of messengers were cloned with the 59-RACE kit from
CLONTECH (Palo Alto, CA) according to the instructions of the
manufacturer. The primer 9A was used for reverse transcription.
The oligonucleotide 15A was used together with the anchor
primer for PCR amplification. After an initial denaturation step of
5 min at 95 C, the first round of amplification was at 95 C for 30
sec, 62 C for 15 sec, and 72 C for 20 sec, 35 times. The second
round was performed with 0.2 ml of the first amplification mix,
using the same parameters and 30 cycles. PCR products were
analyzed by Southern blot using oligonucleotide 8S as a probe.
The positive DNA fragment was purified and cloned into the
SmaI site of pBSK (Stratagene. La Jolla, CA) before sequence
analysis. 39-Ends were amplified using 59-anchored PCR. A
modified oligodT primer (ACTATCGATTCTGGAACCTTCA-
GAGG (T)18GACACGT) was used for the cDNA synthesis. The
first round of PCR amplification was run with VIIS as 59-primer
and P39 (CTATCGATTCTGGAACCTTCAGAGG) as 39-primer;
35 cycles were performed at 95 C for 30 sec, at 58 C for 10 sec,
and at 72 C for 20 sec. The second round was performed with
0.2 ml of the first product, with 1S or 2S as 59-primer. Thirty two
cycles were run at 95 C for 30 sec, at 58 C for 10 sec, and at 72
C for 15 sec. The PCR products were cloned into pBSK and
sequenced. For TRDa1 and TRDa2 cDNA cloning, the amplifi-
cation parameters were 95 C for 30 sec, 56 C for 10 sec, and 72
C for 30 sec and 35 cycles were run. The PCR amplification
products were cloned into pBSK in SmaI. Expression vectors
were constructed by excising TRDa1o rT R D a 2 from pBSK by
BamHI and EcoRI and inserting them in the corresponding sites
of pSG5 (Stratagene). A TGA codon was introduced in TRDa1
using the in vitro mutagenesis kit (CLONTECH) and oligonucle-
otide CTGCTGATGAAG TAGACTGACCTCCGC to allow the
production of the 256–369 protein. To build the translation mu-
tant pSGTRDT, a fragment containing the entire coding se-
quence of TRDa1 was amplified by PCR and cloned in the
BamHI site of a pSGFlag vector so that the reading frame
prevents the translation of the p16a1 protein. Mouse intron 7
was amplified by PCR reaction with oligonucleotides 7S and
15A as primers and 100 ng of genomic DNA from ES cells. Thirty
cycles were performed at 95 C for 30 sec, at 58 C for 10 sec,
and at 72 C for 30 sec. The product was cloned into pBSK
(Stratagene). CAT expression vectors were constructed by in-
serting a 512-bp PstI-PstI fragment (Fig. 1B) into pBAS CAT
(Promega). DNA sequencing was performed on an Applied Au-
tomatic Sequencer (Perkin Elmer).
Purification of polyA1 RNAs, RNase Protection Assay,
and Northern Blot
PolyA
1 RNAs were purified using the “Message Maker” kit
from R&D systems (Minneapolis, MN). RNase protection ex-
periments were performed using the RNase protection assay
system from Promega. The vector used to synthesize the
TRa-specific probe was derived by cloning a PstI fragment
containing intron 7 and exon 8 into the PstI site of pBSK. The
antisense RNA probe was synthesized using T7 RNA poly-
merase (Promega) and [a
32P]UTP (specific activity 800 Ci/
mmol). Hybridizations were carried out overnight at 50 C.
Hybridization mixtures were digested with1Uo fRNAse ONE
at room temperature for 1 h. Northern blots were carried out
using the glyoxal denaturation technique and alkaline transfer
onto Hybond N
1. Hybridization buffer (43SSC, 0.25% low-
fat milk, 1% SDS, 10 mM sodium phosphate, pH 6.8, and 0.1
mg/ml denatured herring sperm DNA) was supplemented
with 1% diethyl pyrocarbonate and incubated overnight at 56
C. Membranes were preincubated1hi nthis solution, and
hybridization was performed overnight at 54 C using 5 ng/ml
of an equimolar mixture of 9A, 3A, and 15A end-labeled
oligonucleotides. RNA quantification was made with a Phos-
phorImager (Molecular Dynamics, Sunnyvale, CA).
In Situ Immunofluorescence and Western Blotting
The No. 21 antibody raised against peptide 229–325 of the
chicken T3Ra1 protein was kindly provided by J. Ghysdael
(Orsay, France). It recognizes a C-terminal epitope common
to the T3Ra1 and T3Ra2 proteins. Immunofluorescence was
performed as previously described (37). The No. 21 antibody
was diluted 1:1000 in Dako diluent (Dako, Copenhagen, Den-
mark) before use. Western blotting were carried out as pre-
viously described (40). Membranes were incubated 2 h with
the No. 21 antibody diluted 1:1000.
Half-Life Measurement of TRDa Products
HeLa cells were transfected with 1 mgo fp 1 6 a 1- and p26a2-
expressing vectors. Thirty six hours after transfection, cells
were labeled with 10 mCi of
35S cell labeling mix (PRO-MIX,
Amersham, Arlington Heights, IL) for 45 min, washed three
times in PBS, then further cultured in
35S-free medium for 0–2
h or 0–5 h. Cells were scraped off the dish in ice-cold PBS,
pelleted, and frozen in liquid nitrogen until used.
MOL ENDO · 1997 Vol 11 No. 9
1288
 at INIST Dpsi Aire Geographique on September 3, 2008  mend.endojournals.org Downloaded from Sequences of Oligonucleotides
7S: GCCAGTCACCTATTGTCTCCATGC; 1S:
CCACTCTTCCTGGAGGTCTTTGA
RS: GAGTGTCGACCTTGTCCTGAAACTGGC;
RA: GAGGGTACCTTCACTTCAATTCCATCCAG
XA: GGAGCTTGGCCACGAGTGGCAT; IXA:
GGTCCCAGAGACTCTAGAACTTG
2S: GCAGCTTGAGCAGCAGCTTGGTG; 8S:
CTGCCTTGCGAAGACCAGATC
VIIS: CTCTGTGATCCTGCTGTTCCACAG; hVIIS:
CTCTGTGGCCCTGCCGCTCCACAG
cVIIS1: GTAATGGGGAGGTGTGTGGGGTATGG;
cVIIS2: AGCCGCTGACAGTGCGCCCCACAG
c9A: CTATCTTATCCACGCAGATCAGCCCCGTCCGG;
9A: GCGGTGGTTGACGTAGTGCTC
15A: CAGCCTGCAGCAGAGCCACTTCCGT; 5S:
GCTGTGCCGCTTCAAGAAGTGCA
1A: CGACTTTCATGTGGAGGAAG; 2A:
CCTGAACAACATGCATTCCGA
3A: TGCGGTGGTTGACGTAGTGCTC
HPRT: GCTGGTGAAAAGGACCTCT; HPRTa:
CACAGGACTAGAACACCTGC
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